In patients with autoimmune Addison disease, there is a rapid decline in steroidogenic capacity once replacement glucocorticoid medication is started.
Patients taking glucocorticoids are at a high risk if they are infected with SARS-CoV-2, according to an editorial article from the Endocrine Society.
The increased mortality rate in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy is mostly related to endocrine and metabolic diseases, infections, and oral and esophageal malignancies.
The most clinically appropriate mode of hydrocortisone administration during major stress in patients with adrenal insufficiency is continuous intravenous hydrocortisone.
The Food and Drug Administration (FDA) has approved Isturisa® (osilodrostat; Recordati) for the treatment of adults with Cushing disease for whom pituitary surgery is not an option or has not been curative.
Gastroenterologists who are members of an EoE consortia are much more likely to routinely screen for adrenal insufficiency in children with eosinophilic esophagitis who are being treated with topical corticosteroids.
No reference criteria can definitively distinguish patients with primary aldosteronism and subclinical Cushing syndrome from those with these conditions alone.
Pheochromocytomas and paragangliomas may be an important cause of secondary osteoporosis.
A significantly lower hair cortisol concentration was observed in patients with asthma compared with healthy controls, suggesting that this measurement may be used to detect individuals at risk for hypocortisolism.
According to results of the phase 3 SONICS trial, levoketoconazole is a safe and effective treatment option for patients with Cushing syndrome.
Researchers examined sex differences in clinical presentation and patient outcomes in ACTH-dependent Cushing syndrome.